Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis
- PMID: 11040277
- DOI: 10.1634/theoncologist.5-5-405
Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis
Abstract
Chronic myeloid leukemia (CML) is a disease of the hematopoietic system, characterized by the presence of the Bcr-Abl oncoprotein. The main characteristics of this disease include adhesion independence, growth factor independence, and resistance to apoptosis. Loss or mutation of the tumor suppressor gene, p53, is one of the most frequent secondary mutations in CML blast crisis. The transition between chronic phase and blast crisis is associated with increased resistance to apoptosis correlating with poor prognosis. This review focuses on the involvement of these two oncoproteins in the development and progression of the apoptotic-resistant phenotype in CML.
Similar articles
-
Chronic myelogenous leukemia: mechanisms underlying disease progression.Leukemia. 2002 Aug;16(8):1402-11. doi: 10.1038/sj.leu.2402577. Leukemia. 2002. PMID: 12145676 Review.
-
Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.Genes Chromosomes Cancer. 2001 May;31(1):10-4. doi: 10.1002/gcc.1112. Genes Chromosomes Cancer. 2001. PMID: 11284030
-
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.Oncotarget. 2017 Feb 14;8(7):10809-10821. doi: 10.18632/oncotarget.14580. Oncotarget. 2017. PMID: 28086219 Free PMC article.
-
[Research advance on molecular genetics of CML blast crisis].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):217-21. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. PMID: 18315935 Review. Chinese.
-
p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.Cancer Genet Cytogenet. 1995 Jul 1;82(1):35-40. doi: 10.1016/0165-4608(94)00282-g. Cancer Genet Cytogenet. 1995. PMID: 7627932
Cited by
-
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.Int J Mol Sci. 2019 Nov 10;20(22):5616. doi: 10.3390/ijms20225616. Int J Mol Sci. 2019. PMID: 31717629 Free PMC article. Review.
-
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.Oncotarget. 2011 Sep;2(9):713-27. doi: 10.18632/oncotarget.333. Oncotarget. 2011. PMID: 21946665 Free PMC article.
-
Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?Biosci Rep. 2013 Nov 25;33(6):e00081. doi: 10.1042/BSR20130067. Biosci Rep. 2013. PMID: 24070327 Free PMC article. Review.
-
Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.Leukemia. 2016 Sep;30(9):1861-8. doi: 10.1038/leu.2016.143. Epub 2016 May 23. Leukemia. 2016. PMID: 27211271 Free PMC article.
-
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.J Cell Mol Med. 2011 Oct;15(10):2057-70. doi: 10.1111/j.1582-4934.2010.01218.x. J Cell Mol Med. 2011. PMID: 21091633 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous